Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H29ClN6O3 |
Molecular Weight | 472.968 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)CN1CCN(CC2=NC(=NO2)C3=CN(CC4CCOCC4)C5=C3C=CC=C5Cl)CC1
InChI
InChIKey=AKWUNZFZIXEOPV-UHFFFAOYSA-N
InChI=1S/C23H29ClN6O3/c24-19-3-1-2-17-18(13-30(22(17)19)12-16-4-10-32-11-5-16)23-26-21(33-27-23)15-29-8-6-28(7-9-29)14-20(25)31/h1-3,13,16H,4-12,14-15H2,(H2,25,31)
Molecular Formula | C23H29ClN6O3 |
Molecular Weight | 472.968 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 12:13:47 GMT 2023
by
admin
on
Sat Dec 16 12:13:47 GMT 2023
|
Record UNII |
505K9LJ4MX
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID50648411
Created by
admin on Sat Dec 16 12:13:47 GMT 2023 , Edited by admin on Sat Dec 16 12:13:47 GMT 2023
|
PRIMARY | |||
|
25006676
Created by
admin on Sat Dec 16 12:13:47 GMT 2023 , Edited by admin on Sat Dec 16 12:13:47 GMT 2023
|
PRIMARY | |||
|
505K9LJ4MX
Created by
admin on Sat Dec 16 12:13:47 GMT 2023 , Edited by admin on Sat Dec 16 12:13:47 GMT 2023
|
PRIMARY | |||
|
1050478-18-6
Created by
admin on Sat Dec 16 12:13:47 GMT 2023 , Edited by admin on Sat Dec 16 12:13:47 GMT 2023
|
PRIMARY | |||
|
LBP-1 (drug)
Created by
admin on Sat Dec 16 12:13:47 GMT 2023 , Edited by admin on Sat Dec 16 12:13:47 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Novel, low brain penetrant, orally bioavailable CB1 receptor agonists were designed using calculated polar surface area as a predictor of CNS permeability. This approach led to the discovery of LBP1, an orally bioavailable, low brain penetrant CB1 receptor agonist with robust activity in rodent models of neuropathic pain and a good preclinical therapeutic profile.
|